Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
$28.45
▼ -$0.36 (-1.25%)Today
Open
$28.58
High
$28.69
Low
$28.38
Volume
23.5M
$23.5852-Week Range$29.21
Current: $28.45 · Near 52W High
MARKET CAP
$162.2B
P/E (TTM)
37.4x
P/B RATIO
1.9x
ROE
5.0%
EPS (TTM)▲ 2.6% Rev YoY
$0.76
DIVIDEND YIELD
6.05%
BETA
0.30
Defensive / low-beta
Company Info
Industry
Drug Manufacturers - General
Country
United States
Leadership
DA
Dr. Albert Bourla D.V.M., Ph.D.
Chief Executive Officer
Stock Score
Best Value23/ 100
Val
33
Grw
8
Qly
28
Value 40%·Growth 35%·Quality 25%
Price History
$28.45▲ $3.90 (15.89%)
Overlays
Oscillators
Generating analysis...
01 / Income Statement
Income Statement
Revenue & Margin Trend
| Period | Revenue | OpEx | EBITDA | Net Income | EPS |
|---|---|---|---|---|---|
| 2022 | $101.17B | $28.71B | $41.03B | $31.37B | $5.47 |
| 2023 | $59.55B▼ | $30.18B | $9.56B | $2.12B▼ | $0.37 |
| 2024 | $63.63B▲ | $30.84B | $18.13B | $8.03B▲ | $1.41 |
| 2025 | $62.58B▼ | $29.11B | $16.78B | $7.77B▼ | $1.36 |
02 / Balance Sheet
Balance Sheet
Cash & Equivalents
$1.14B
Total Debt
$63.96B
Assets Distribution
Current Assets
Non-Current Assets
Liabilities & Equity
Current Liabilities
Non-Current Liabilities
Equity
03 / Cash Flow
Cash Flow
Positive free cash flow of $9.1B — 78% of operating cash flow.
Operating CF
$11.7B
Free Cash Flow
$9.1B
Investing CF
-$1.4B
Financing CF
-$10.3B
Cash Flow Mix
Operating Cash$11.7B
Investing Cash-$1.4B
Financing Cash-$10.3B
Net Change$49M
FCF Generation
The company converts 78% of operating cash flow into free cash flow, providing ample flexibility for capital allocation.
CapEx Burden
Capital expenditures consume $1.4B of operating cash. Monitor for maintenance vs. growth CapEx split.
Is the cash flow sustainable?
Positive Free Cash Flow
The company has flexibility for dividends, buybacks, debt reduction, or reinvestment in growth opportunities.
04 / Financial Ratios
Financial Ratios
Profitability
Gross Margin
74.3%
Gross Profit / Revenue
Operating Margin
27.8%
Op. Income / Revenue
Net Margin
12.4%
Net Income / Revenue
ROIC
5.2%
Return on Invested Capital
Liquidity & Leverage
Current Ratio
1.16x
Current Assets / Current Liab.
Cash Ratio
0.03x
Cash / Current Liab.
Debt-to-Equity
0.74
Total Debt / Equity
Asset Turnover
0.30
Revenue / Total Assets
Returns
ROE
5.0%
Return on Equity
ROA
5.8%
Return on Assets
EPS (TTM)
$0.76
Earnings Per Share
06 / Historical Trends
Historical Trends
Revenue
-14.8% CAGRNet Income
-37.2% CAGREPS
-37.1% CAGR05 / Dividends
Dividends & Yield
Dividend Yield
6.05%
Annual
Annual Dividend
$1.72
Per Share
Payout Ratio
226.5%
Div / EPS
Est. Div Growth
+1.0%
Approx. YoY
Dividend Safety Assessment
The payout ratio of 226% is elevated and may be at risk if earnings decline.
Recent Dividend Payments
| Date | Amount |
|---|---|
| 2026-07-24 | $0.43 |
| 2026-05-08 | $0.43 |
| 2026-01-23 | $0.43 |
| 2025-11-07 | $0.43 |
| 2025-07-25 | $0.43 |
| 2025-05-09 | $0.43 |
| 2025-01-24 | $0.43 |
| 2024-11-08 | $0.42 |
| 2024-07-26 | $0.42 |
| 2024-05-09 | $0.42 |
Institutional Ownership
Moderate Institutional Support
Top 3 institutional holders control 21.2% of shares, providing a stable foundation of institutional capital.
Retail Influence
Lower institutional concentration means retail sentiment and broader market trends may drive price action more noticeably.
Top Institutional Holders
Blackrock Inc.9.29%
529.67M shares
Vanguard Capital Management LLC6.53%
372.15M shares
State Street Corporation5.39%
307.09M shares
Geode Capital Management, LLC2.37%
135.28M shares
Vanguard Portfolio Management LLC2.09%
119.24M shares
Top ETFs Holding
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%
180.94M shares
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%
147.7M shares
iShares Trust-iShares Core S&P 500 ETF1.37%
78.36M shares
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.29%
73.7M shares
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.21%
69.05M shares
07 / Market Events
Market Events
Upcoming Earnings
NOV
3TUE
DateNov 3, 2026
DayTuesday
Revenue Est.$15.9B
EPS Est.$0.76
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-17 | Forward | 1054:1000 |
| 1999-07-01 | Forward | 3:1 |
| 1997-07-01 | Forward | 2:1 |
| 1995-07-03 | Forward | 2:1 |
| 1991-04-01 | Forward | 2:1 |
08 / Market Intelligence
Market Intelligence
Analyst Consensus
Consensus (28 Ratings)
Buy
Strong Buy
2
Buy
8
Hold
16
Sell
1
Strong Sell
1
Recent Insider Trades
BOURLA ALBERT
Chief Executive Officer
Purchase
38,000 shs
DAMICO JENNIFER B.
Officer
Sale
3,278 shs
BLAYLOCK RONALD E
Director
Purchase
39,231 shs
BUCKLEY MORTIMER J.
Director
Purchase
37,632 shs
Price Targets
Upside to Mean+0.5%
$25$29$36
Low
$25.00
Mean
$28.61
Median
$28.00
High
$35.75
Earnings History
Beat Rate
4/4
Avg Surprise
+17.6%
| Period | Est. EPS | Act. EPS | Surprise |
|---|---|---|---|
| 2025-09 | $0.63 | $0.87 | +37.4% |
| 2025-12 | $0.57 | $0.66 | +16.2% |
| 2026-03 | $0.72 | $0.75 | +3.9% |
| 2026-06 | $0.68 | $0.77 | +12.9% |